Mallinckrodt closed at $21.51 in the latest trading session, marking a +0.61% move from the prior day. This change outpaced the S&P 500's 0.46% loss on the day. Elsewhere, the Dow lost 0.13%, while the tech-heavy Nasdaq lost 0.63%.
Prior to today's trading, shares of the specialty pharmaceutical company had lost 10.02% over the past month. This has lagged the Medical sector's gain of 0.39% and the S&P 500's gain of 1.08% in that time.
MNK will be looking to display strength as it nears its next earnings release. The company is expected to report EPS of $1.79, up 36.64% from the prior-year quarter. Meanwhile, our latest consensus estimate is calling for revenue of $775.39 million, up 35.41% from the prior-year quarter.
MNK's full-year Zacks Consensus Estimates are calling for earnings of $8.22 per share and revenue of $3.25 billion. These results would represent year-over-year changes of +2.62% and +21.39%, respectively.
Investors might also notice recent changes to analyst estimates for MNK. Recent revisions tend to reflect the latest near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 9.56% higher within the past month. MNK is holding a Zacks Rank of #1 (Strong Buy) right now.
Investors should also note MNK's current valuation metrics, including its Forward P/E ratio of 2.6. This represents a discount compared to its industry's average Forward P/E of 6.64.
We can also see that MNK currently has a PEG ratio of 0.22. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. MNK's industry had an average PEG ratio of 1.17 as of yesterday's close.
The Medical - Generic Drugs industry is part of the Medical sector. This group has a Zacks Industry Rank of 85, putting it in the top 34% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks. Com to follow all of these stock-moving metrics, and more, in the coming trading sessions.
Image: Bigstock
Mallinckrodt (MNK) Gains As Market Dips: What You Should Know
Mallinckrodt closed at $21.51 in the latest trading session, marking a +0.61% move from the prior day. This change outpaced the S&P 500's 0.46% loss on the day. Elsewhere, the Dow lost 0.13%, while the tech-heavy Nasdaq lost 0.63%.
Prior to today's trading, shares of the specialty pharmaceutical company had lost 10.02% over the past month. This has lagged the Medical sector's gain of 0.39% and the S&P 500's gain of 1.08% in that time.
MNK will be looking to display strength as it nears its next earnings release. The company is expected to report EPS of $1.79, up 36.64% from the prior-year quarter. Meanwhile, our latest consensus estimate is calling for revenue of $775.39 million, up 35.41% from the prior-year quarter.
MNK's full-year Zacks Consensus Estimates are calling for earnings of $8.22 per share and revenue of $3.25 billion. These results would represent year-over-year changes of +2.62% and +21.39%, respectively.
Investors might also notice recent changes to analyst estimates for MNK. Recent revisions tend to reflect the latest near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 9.56% higher within the past month. MNK is holding a Zacks Rank of #1 (Strong Buy) right now.
Investors should also note MNK's current valuation metrics, including its Forward P/E ratio of 2.6. This represents a discount compared to its industry's average Forward P/E of 6.64.
We can also see that MNK currently has a PEG ratio of 0.22. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. MNK's industry had an average PEG ratio of 1.17 as of yesterday's close.
The Medical - Generic Drugs industry is part of the Medical sector. This group has a Zacks Industry Rank of 85, putting it in the top 34% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks. Com to follow all of these stock-moving metrics, and more, in the coming trading sessions.